- epidimiology:
- risks:
- symptoms/signs:
- histo/pathology:
- pathogenesis:
- dx:
- staging:
- disease course:
- treatment:



L19: AML + MDS notes:
	- leukemogenesis: decreased differentiation + increased proliferation
	- AML risks:
		- topoIIi (del 11q23) + akylators (del 5+7)
		- radiation/solvents
		- downs, li fraumeni (p53), fanconi's anemia
	- Sx: bleeding/bruising/ecchymoses/petechiae, hepatosplenomegaly, dyspea etc
	- bad muts: tp53, SF3B1, inv(3), BCR-ABL1
	- intermediate muts: FLT3, t(9, 11), 
	- good muts: t(8, 21), inv(16), NPM1 w/o FLT3
	- therapy:
		- 7+3, SCT
		- gemtuzumab: CD33
		- FLT3 muts: midostaurin, gilteritinib
	- induction -> aplasia -> infections
	- paradigm:
		- low risk t(8, 21), inv(16): 7+3
		- high risk: allo SCT
		- med risk: if donor -> allo sct
		- old/weak -> venetoclax
	- median age ~70

	- APL: 
		- 10% AML,
		- bleeding diathesis
		- t(15, 17)
		- use ATRA + arsenic
		- APL differentiation syndrome
			- early: fever, dyspnea, weight gain
			- late: pulm infiltrates, pleural/pericardial effusions
			- use steroids
			- 30% of APL during induction
	- MDS:
		- BM + PM blasts < 20%
		- IPSS-R scoring: uses cyto, BM blast %, ANC, platelets, hemoglobin
		- 5q- syndrome:
			- more female
			- mild, anemia + thrombocytosis
			- mild neutropenia
			- tx: lenalidomide
		- tx:
			- young MDS -> allo SCt
			- no HLA, stable -> supportive + low tox therapy
			- no HLA, young or progressive -> low: lenalidomide, high: hypomethylators or AML induction
			- ring-sideroblasts -> luspatercept




L20 ALL + CLL:
	- ALL:
		- rare, mostly kids
		- worse prognosis:
			- older
			- t(9, 22)
			- T-cell phenotype
			- MRD
		- good prognosis:
			- t(12, 21)
		- risks: radiation, downs
		- symptoms:
			- bleeding
			- effective neutropenia
			- fatigue, dyspnea, dizziness
			- fever, bone pain, CNS symptoms
			- ecchymoses, petechiae
			- splenomegaly
		- T cell - ALL: mediastinal mass, SVC-like syndrome
		- pathology:
			- large and sticky pull apart bread
			- open chromatin
			- light purple cytoplasm
			- no granules

		- markers:
			- TdT+: blast
			- CD10: B-cell lymphoblast

		- tumor lysis syndrome:
			- all up (phos, urea, K+)
			- Ca+ down (phos soaks up)
			- tx: allopurinol, rasburicase, hydration
		- tx:
			- relapse -> allo SCT

	- CLL:
		- most common adult leukemia
		- median age ~70
		- 1/3 no tx, 1/3 deferred tx
		- richter transformation: rare transform to DLBCL
		- mutatated IGHV -> more differentiated -> better prognosis
		- pathology:
			- smudge cells
			- soccer ball look
			- Crushed Little Lymphocytes

		- presentation:
			- lymphocytosis
			- lymphadenopathy
			- cytopenia symptoms
			- splenomegaly + weight loss

		- markers:
			- CD5, CD19/20/23

		- staging:
			- 0: >5000/ul monoclonal lymphocytosis + markers
			- 1: lymphadenopathy
			- 2: splenomegaly
			- 3: hemoglobin < 11
			- 4: platelets < 100k
		- prognosis:
			- good: 13q-
			- bad: 17p-
		- symptoms:
			- ITP
			- AIHA (autoimmune hemolytic anemia)
			- hypogammaglobilenmia
			- pure red cell aplasia (PRCA)

		- tx:
			- treat stage 3/4 or symptomatic
			- FCR/ibrutinib/venetoclax



L25 CML + NPMs:
	- CML:
		- 45-55 yo
		- slightly male
		- presentation:
			- incidental
			- constitutional symptoms
			- hepatosplenomegaly
			- ecchymoses
		- pathology:
			- basophilia, thrombocytosis
			- peripheral blood: looks like bone marrow
			- bone marrow: hypercellular, increased myeloid:erythroid
		- t(9, 22):
			- tons of things
		- phases:
			- chronic (4-6 years)
			- accelerated: variable
			- blast crisis:
				- 3-6 mo survival
				- either myeloid or lymphoid
		- tx: imatinib, nilotinib
			- complete response:
				- normal WBC, platelets, no immature cells
				- 0% t(9, 22) cells
				- > 4.5 log reduction BCR-ABL transcripts
			- partial response: 1-35% t(9, 22) cells
			- major response: >3 log reduction BCR-ABL transcripts
			- can stop meds if responded

	- polycythemia vera (PV):
		- high HGB/HCT
		- thrombosis
		- Sx:
			- pruritus: especially post shower
			- plethora
			- splenomegaly
			- fatigue

		- JAK2 V617F:
			- 95% of PV
			- EPO signaling uses JAK2 pathway -> increased RBCs

		- pathology:
			- bone marrow: moderate/marked hypercellularity
			- large clustered megakaryocytes
			- decreased iron stores
			- increased reticulin fibers
		- dx:
			- Hgb > 16.5 + HCT > 49%
			- BM biopsy: hypercellularity + pleomorphic mature megakaryocytes
			- JAK2 mutation
			- minor: low EPO

		- tx: phlebotomy, etc
		- 3% mortality each year
			- thrombosis/bleeding
			- transform to AML or PMF

	- essential thrombocytosis (ET):
		- presentation:
			- high platelets
			- thrombosis
			- puritus: especially post shower
			- erythromelalgia
			- splenomegaly
		- genetics:
			- 50% JAK2 V617F
			- 35% calreticulin muts: mut CALR activates MPl
			- 5% MPL (thrombopoetin receptor)

		- dx:
			- platelet > 450 for 2+ months
			- BM biopsy: megakaryocyte proliferation
			- no evidence of CML, MDS, PV, or PMF
			- JAK2, CALR, or MPL mut
			- minor: clonal marker or no reactive thrombocytosis

		- tx:
			- low dose aspirin
			- etc
		- course:
			- thrombosis
			- 1% untreated -> AML
			- 4-8% -> PMF

	- primary myelofibrosis (PMF):
		- pathology:
			- BM fibrosis
			- bizarre megakaryocyte hyperplasia
			- extramedullary hematopoiesis
				- in spleen, liver, etc
			- teardrop RBCs
			- blood looks like marrow	
		- presentation:
			- splenomegaly
			- anemia
			- bleeding/bruising
			- infection
			- cachexia
		- dx:
			- megakaryocyte atypia + reticulin fibers grade 2/3
			- no evidence of CML, PV, ET, or MDS
			- JAK2, CALR, MPL mut, other clone or no reactive fibrosis
			- minor:
				- leukocytos > 11
				- high LDH
				- splenomegaly
				- anemia
				- leukoerythroblastosis
			- all major + 1 minor

		- course:
			- life expectancy: variable ~5 years
			- risks:
				- age, Hgb < 10, WBC > 25, blasts > 1%
				- constitutional symptoms
				- inv(3), del 5/7, +8, del 11q23
				- platelets < 100
			- 10-15% -> AML

		- tx: supportive SETHS + active JITS